Cadrenal Therapeutics, Inc.
CVKD Nasdaq
SEC CIK 1937993
Follow Cadrenal Therapeutics
Weekly email: filings, results
Net income
−$1.2M
+53.6% vs same quarter last year
EPS, diluted
−$0.31
+76.3% vs same quarter last year
Operating cash flow
−$1.9M
+18.7% vs same quarter last year
Operating income
−$1.3M
+53.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$13.2M |
| FY24 | −$10.7M |
| FY23 | −$8.4M |
| FY22 | - |
| FY08 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$12.6M |
| FY24 | −$7.4M |
| FY23 | −$3.5M |
| FY22 | - |
| FY08 | - |